Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3No longer available 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

CNS 4Sarcoma 2

Conditions

Glioblastoma 3Neoplasms 2Gliosarcoma 2Brain Neoplasms 2Recurrence 1Glioma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × rindopepimut × Clear all
NCT01498328 2020-02-17

ReACT

Celldex Therapeutics

Phase 2 Completed
127 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence, Gliosarcoma

NCT00458601 2018-01-16

ACT III

Celldex Therapeutics

Phase 2 Completed
82 enrolled
CNS

Glioma

NCT01480479 2018-01-16

ACT IV

Celldex Therapeutics

Phase 3 Completed
745 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Neoplasms, Gliosarcoma

NCT03068650 2017-10-18

CDX-110

Celldex Therapeutics

No longer available
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡